Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
India continues to face a major maternal nutrition challenge, with nearly 60% of women affected by anaemia and more than 70% experiencing calcium deficiency
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Launches advanced bone density systems in India & Dubai
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Subscribe To Our Newsletter & Stay Updated
